Mechanism of PARP inhibitor resistance and potential overcoming strategies
PARP inhibitors (PARPi) are a kind of cancer therapy that targets poly (ADP-ribose) polymerase. PARPi is the first clinically approved drug to exert synthetic lethality by obstructing the DNA single-strand break repair process. Despite the significant therapeutic effect in patients with homologous r...
Main Authors: | Xiaoyu Fu, Ping Li, Qi Zhou, Ruyuan He, Guannan Wang, Shiya Zhu, Amir Bagheri, Gary Kupfer, Huadong Pei, Juanjuan Li |
---|---|
Format: | Article |
Language: | English |
Published: |
KeAi Communications Co., Ltd.
2024-01-01
|
Series: | Genes and Diseases |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2352304223000661 |
Similar Items
-
PARP Inhibitors Resistance: Mechanisms and Perspectives
by: Elena Giudice, et al.
Published: (2022-03-01) -
Hematological Toxicities with PARP Inhibitors in Prostate Cancer: A Systematic Review and Meta-Analysis of Phase II/III Randomized Controlled Trials
by: Gartrell C. Bowling, et al.
Published: (2023-10-01) -
PARP Inhibitors in Combination with Radiotherapy: To Do or Not to Do?
by: Amelia Barcellini, et al.
Published: (2021-10-01) -
Interactions of PARP1 Inhibitors with PARP1-Nucleosome Complexes
by: Natalya Maluchenko, et al.
Published: (2022-10-01) -
PARP Inhibitors: A Major Therapeutic Option in Endocrine-Receptor Positive Breast Cancers
by: Laetitia Collet, et al.
Published: (2022-01-01)